ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Blood-based multivariate methylation risk score for cognitive impairment and dementia.
Abstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- DEVELOPMENT AND APPLICATION OF BRAIN TISSUE BASED MULTI-OMICS PROFILE SCORES FOR ALZHEIMER'S DISEASE.Research square · 2026Article
- Epigenomic subtypes of late-onset Alzheimer's disease reveal distinct microglial signatures.Acta neuropathologica · 2026Article
- ACMSD methylation in peripheral blood is associated with dynamic functional connectivity pattern in adolescent MDD patients.Epigenetics · 2025Article
- Association of DRD4 promoter-associated methylation with mild cognitive impairment in Han and Uygur populations.European journal of medical research · 2025Article
- Prematurity and Epigenetic Regulation ofBiomedicines · 2025Article
- Epigenetic clocks and DNA methylation biomarkers of brain health and disease.Nature reviews. Neurology · 2025Review
- Review
- Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- A brain DNA co-methylation network analysis of psychosis in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Article
- Epigenetic age acceleration and neurotrophin signaling pathways in cancer-related cognitive impairment: a longitudinal, prospective cohort study.Frontiers in aging · 2025Article
- Blood-based multivariate methylation risk score for cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors.
Jarno KoetsierDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Rachel CavillDepartment of Advanced Computing Sciences (DACS), Faculty of Science and Engineering (FSE), Maastricht University, Maastricht, The Netherlands.
Rick ReijndersDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Joshua HarveyMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Jan HomannInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Morteza KouhsarMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Kay DeckersDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Sebastian KöhlerDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Lars M T EijssenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Daniel L A van den HoveDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Ilja DemuthDepartment of Endocrinology and Metabolic Diseases (including Division of Lipid Metabolism), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Sandra DüzelCenter for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany.
Alzheimer's Disease Neuroimaging Initiative
Rebecca G SmithMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Adam R SmithMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Joe BurrageMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Emma M WalkerMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Gemma ShirebyMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Eilis HannonMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Emma DempsterMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Tim FraylingMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Jonathan MillMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Valerija DobricicLübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany.
Peter JohannsenDanish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark.
Michael WittigInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Rik VandenbergheLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
Jolien SchaeverbekeLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
Yvonne Freund-LeviDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Lutz FrölichDepartment of Geriatric Psychiatry, Central Institute of Mental Health; Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.
Philip ScheltensDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Giovanni FrisoniMemory Center, Geneva University and University Hospitals; on behalf of the AMYPAD Consortium, Genève, Switzerland.
Olivier BlinAix-Marseille University-CNRS, Marseille, France.
Jill C RichardsonNeuroscience Therapeutic Area, GlaxoSmithKline R&D, Stevenage, Hertfordshire, UK.
Régis BordetUniversité de Lille, Lille Cedex, France.
Sebastiaan EngelborghsDepartment of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium.
Ellen de RoeckDepartment of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium.
Pablo Martinez-LageCenter for Research and Advanced Therapies, CITA-Alzheimer Foundation, Gipuzkoa, Spain.
Mikel TaintaCenter for Research and Advanced Therapies, CITA-Alzheimer Foundation, Gipuzkoa, Spain.
Alberto LleóNeurology Department, Centro de Investigación en Red en enfermedades neurodegenerativas (CIBERNED), Hospital Sant Pau, Sant Antoni Maria Claret, Barcelona, Spain.
Isabel SalaNeurology Department, Centro de Investigación en Red en enfermedades neurodegenerativas (CIBERNED), Hospital Sant Pau, Sant Antoni Maria Claret, Barcelona, Spain.
Julius PoppUniversity Hospital of Psychiatry Zürich, University of Zürich, Zürich, Switzerland.
Gwendoline PeyratoutDepartment of Psychiatry, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Frans VerheyDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Magda Tsolaki1st Department of Neurology, School of Medicine, `Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation, Aristotle University of Thessaloniki, and Alzheimer Hellas, Macedonia, Balkan Center, Thessaloniki, Greece.
Ulf AndreassonInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden.
Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden.
Johannes StrefferAC Immune SA, formerly Janssen R&D, LLC. Beerse, Belgium at the time of study conduct, Lausanne, Switzerland.
Stephanie J B VosDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Simon LovestoneUniversity of Oxford, Oxford, United Kingdom; Currently at Johnson & Johnson Innovative Medicines, Beerse, Belgium.
Pieter-Jelle VisserDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
Christina M LillInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Lars BertramLübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany.
Katie LunnonMedical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Ehsan PishvaDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-8964-0682
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MA multi-omic approach to elucidate novel disease mechanisms and biomarkers for psychosis in Alzheimer’s diseaseR01AG067015 · NIA · UNIVERSITY OF EXETER · PI KOFLER, JULIA K, LUNNON, KATIE · 2019 to 2023
$1.6MAD Strategic Fund and the Alzheimer's Association #ADSF-21-831376-CAD Strategic Fund and the Alzheimer's Association #ADSF-21-831377-CAD Strategic Fund and the Alzheimer's Association #ADSF-21-831381-CALF-agreement #ALFGBG-715986ALF-agreement #ALFGBG-965240Alzheimer Drug Discovery Foundation (ADDF), USA #201809-2016862Alzheimer's Association 2021 Zenith Award SG-23-1038904 QCAlzheimer's Association 2021 Zenith Award ZEN-21-848495Alzheimer's Society UK AS-PG-14-038Biomedical research CentreBluefield ProjectCure Alzheimer's Fund EPIC4ADDOD ADNI (Department of Defense award W81XWH-12-2-0012EU Joint Programme - Neurodegenerative Disease Research 2021″ EPIC4NDEU Joint Programme - Neurodegenerative Disease Research 2021″ JPND2021European Union Joint Program for Neurodegenerative Disorders JPND2019-466-236European Union Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Union's Horizon Europe research and innovation programme 101053962European Union's Seventh Framework Program FP7/2007-2013Familjen Erling-Perssons StiftelseHeisenberg grant of the German Research Foundation LI 2654/4-1Hjärnfonden, Sweden #ALZ2022-0006Hjärnfonden, Sweden #FO2017-0243Hjärnfonden, Sweden #FO2022-0270Innovative Medicines Initiative Joint Undertaking 115372Marie Skłodowska-Curie 860197Medical Research CouncilNational Institute for Health and Care ResearchNational Institute for Health and Care Research University College London Hospitals Biomedical Research CentreNational Institute of Aging (NIA)National Institutes of Health (NIH) R01AG067015NIA NIH HHS R01 AG067015NIA NIH HHS U01 AG024904NIBIB NIH HHSOlav Thon FoundationStiftelsen för Gamla TjänarinnorSwedish Alzheimer Foundation #AF-930351Swedish Alzheimer Foundation #AF-939721Swedish Alzheimer Foundation #AF-968270Swedish Research Council #2017-00915Swedish Research Council #2019-02397Swedish Research Council #2022-00732Swedish Research Council #2022-01018Swedish State Support for Clinical Research #ALFGBG-71320UK Dementia Research InstituteZonMw Memorabel/Alzheimer Nederland 733050516
Abstract
introductionThe established link between DNA methylation and pathophysiology of dementia, along with its potential role as a molecular mediator of lifestyle and environmental influences, positions blood-derived DNA methylation as a promising tool for early dementia risk detection.
methodsIn conjunction with an extensive array of machine learning techniques, we employed whole blood genome-wide DNA methylation data as a surrogate for 14 modifiable and non-modifiable factors in the assessment of dementia risk in independent dementia cohorts.
resultsWe established a multivariate methylation risk score (MMRS) for identifying mild cognitive impairment cross-sectionally, independent of age and sex (P = 2.0 × 10 DISCUSSION: Our work shows the potential of employing blood-derived DNA methylation data in the assessment of dementia risk. HIGHLIGHTS: We used whole blood DNA methylation as a surrogate for 14 dementia risk factors. Created a multivariate methylation risk score for predicting cognitive impairment. Emphasized the role of machine learning and omics data in predicting dementia. The score predicts cognitive impairment development at the population level.
Indexed as
Cognitive DysfunctionDementiaDNA MethylationAgedAged, 80 and overAlzheimer DiseaseCross-Sectional StudiesFemaleHumansMachine LearningMaleProspective StudiesRisk AssessmentRisk FactorsagingAlzheimer's diseasedementiaDNA methylationepigeneticsmachine learningmild cognitive impairmentsParkinson's diseaserisk prediction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.